Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

BACKGROUND: Type 2 diabetes mellitus is a progressive metabolic disease necessitating therapies with sustained efficacy and safety over time. Exenatide once weekly (ExQW), an extended-release formulation of the glucagon-like peptide-1 receptor agonist exenatide, has demonstrated improvements in glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: MacConell, Leigh, Pencek, Richard, Li, Yan, Maggs, David, Porter, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555554/
https://www.ncbi.nlm.nih.gov/pubmed/23358123
http://dx.doi.org/10.2147/DMSO.S35801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555554/
https://www.ncbi.nlm.nih.gov/pubmed/23358123
http://dx.doi.org/10.2147/DMSO.S35801

Ejemplares similares